RBC on Biohaven Pharmaceutical Holding (BHVN): 'Stock Reaction Overdone On Bipolar Miss'
March 4, 2025 10:26 AM
RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $61.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
